$500k govt grant expands GBS project to neonates
Filed with ASX · · 3 pages · English
Nexsen Limited (ASX:NXN) (“Nexsen” or the “Company”) is pleased to announce the expansion of its rapid point-of-care diagnostic portfolio following the award of a $500,000 non-dilutive grant to RMIT University under the Commonwealth’s Australia’s Economic Accelerator (AEA) Ignite program, with Nexsen as the Commercialisation partner on the project. The project “Transforming Neonatal Care with a Ra
Earlier from Nexsen
- Investor Presentation
- Nexsen Appoints Global Clinical Leader to the Board
- Quarterly Report - Q1 FY26
- Nexsen launches clinical trial for GBS Rapid Sensor
Later from Nexsen
- Quarterly Report - Q2 FY26
- Half Yearly Report and Accounts
- FDA feedback derisks US approval pathway for StrepSure
- Nexsen accelerates global rollout for StrepSure
- HK$6 million grant awarded to advance Asia-Pacific execution
Follow Nexsen into a list and get an email when it puts out news.
Follow Nexsen